Business Context and Reporting Period
This Form 8-K Current Report was filed by Eledon Pharmaceuticals, Inc. (formerly Novus Therapeutics, Inc.) on January 4, 2021. The report details a corporate name change effective January 5, 2021, and associated updates to the company's Certificate of Incorporation and Bylaws.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and administrative changes rather than financial performance.
Material Changes
- Corporate Name: Changed from "Novus Therapeutics, Inc." to "Eledon Pharmaceuticals, Inc."
- Trading Symbol: Changed from "NVUS" to "ELDN" on the Nasdaq Capital Market.
- CUSIP Number: Updated to 28617K101.
- Effective Date: All changes became effective on January 5, 2021.
Guidance, Outlook, and Risks
The filing states that the name change does not affect the rights of the Company's stockholders. No financial guidance, outlook, management commentary on operations, or specific risk factors were disclosed in this document. The press release referenced in Item 8.01 is furnished but not deemed "filed" for liability purposes under Section 18 of the Exchange Act.
Investor Verification Checklist
- Confirm the new ticker symbol "ELDN" is active on the Nasdaq Capital Market.
- Verify the new CUSIP number 28617K101 for trading and settlement purposes.
- Review the attached Certificate of Amendment (Exhibit 3.1) and Amended and Restated Bylaws (Exhibit 3.2) for any future governance implications.
- Check subsequent filings for the first financial report under the new corporate name.